Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials

Good news! Could that be a game changer? This approach may not be limited to rare diseases. This may only be the beginning!

"Immusoft makes history with the first engineered B cell investigational therapy cleared for human trials

Immusoft seeks to improve the treatment of MPS I, a rare childhood disease, through the use of its Immune System Programming (ISP™) approach that utilizes B cells as re-dosable biofactories for therapeutic protein delivery

The company has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ISP-001 in MPS I (Mucopolysaccharidosis type I) and will launch its Phase 1 study this year ..."

Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials - Immusoft